Aurobindo Pharma traded at 526.60 this Friday June 24th, increasing 9.10 or 1.76 percent since the previous trading session. Looking back, over the last four weeks, Aurobindo Pharma gained 0.67 percent. Over the last 12 months, its price fell by 44.59 percent. Looking ahead, we forecast Aurobindo Pharma to be priced at 502.80 by the end of this quarter and at 460.88 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
526.60
Daily Change
1.76%
Yearly
-44.59%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Cipla 934.00 0.65 0.07% -2.41%
Dr.Reddys Laboratories 4,310.00 15.10 0.35% -18.82%
Hindustan Unilever 2,305.95 53.35 2.37% -5.83%
Sun Pharmaceuticals 823.50 -1.40 -0.17% 22.50%
UPL 641.00 7.80 1.23% -20.39%

Indexes Price Day Year
NIFTY 50 15699 142.60 0.92% -1.02%

Aurobindo Pharma
Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.